Literature DB >> 35138599

Treatments on the Horizon: Breast Cancer Patients with Central Nervous System Metastases.

Aaron Kaplan1,2, Min Jun Li3, Rachna Malani4.   

Abstract

PURPOSE OF REVIEW: The goal of this paper is to provide a review on the current emerging management strategies as described in the literature pertaining to breast cancer and central nervous system metastases. As systemic oncology treatments evolve, so are new approaches to the management of central nervous system metastases from breast cancer. RECENT
FINDINGS: In this review, we describe how novel treatment strategies have evolved from standard chemotherapy to more targeted approaches, innovative drug delivery methodologies, immunotherapeutics, and radiotherapeutic approaches. We describe innovative treatment strategies on the horizon for breast cancer and central nervous metastases. Future therapeutics may be better able to penetrate through the blood-brain-barrier bypassing limitations from standard therapies. These pioneering strategies will hopefully improve patients' quality of life as well as survival.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Blood–brain-barrier; Brain metastases; Breast Cancer; CAR-T; Immunotherapy; Intrathecal treatment; Leptomeningeal metastases; Radiation therapy; Systemic treatment

Mesh:

Year:  2022        PMID: 35138599     DOI: 10.1007/s11912-022-01206-2

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  68 in total

1.  Survival of breast cancer patients with meningeal carcinomatosis.

Authors:  H Gauthier; M N Guilhaume; F C Bidard; J Y Pierga; V Girre; P H Cottu; V Laurence; A Livartowski; L Mignot; V Diéras
Journal:  Ann Oncol       Date:  2010-04-29       Impact factor: 32.976

2.  EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours.

Authors:  E Le Rhun; M Weller; D Brandsma; M Van den Bent; E de Azambuja; R Henriksson; T Boulanger; S Peters; C Watts; W Wick; P Wesseling; R Rudà; M Preusser
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

3.  Determinants of prolonged survival for breast cancer patient groups with leptomeningeal metastasis (LM).

Authors:  Anna Niwińska; Katarzyna Pogoda; Wojciech Michalski; Michał Kunkiel; Agnieszka Jagiełło-Gruszfeld
Journal:  J Neurooncol       Date:  2018-02-12       Impact factor: 4.130

Review 4.  Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.

Authors:  Brian Leyland-Jones
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

Review 5.  Chemotherapy delivery issues in central nervous system malignancy: a reality check.

Authors:  Leslie L Muldoon; Carole Soussain; Kristoph Jahnke; Conrad Johanson; Tali Siegal; Quentin R Smith; Walter A Hall; Kullervo Hynynen; Peter D Senter; David M Peereboom; Edward A Neuwelt
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

6.  The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.

Authors:  Paul W Sperduto; Norbert Kased; David Roberge; Samuel T Chao; Ryan Shanley; Xianghua Luo; Penny K Sneed; John Suh; Robert J Weil; Ashley W Jensen; Paul D Brown; Helen A Shih; John Kirkpatrick; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan P S Knisely; Christina Maria Sperduto; Nancy Lin; Minesh Mehta
Journal:  J Neurooncol       Date:  2013-03-06       Impact factor: 4.130

7.  Brain metastases free survival differs between breast cancer subtypes.

Authors:  A Berghoff; Z Bago-Horvath; C De Vries; P Dubsky; U Pluschnig; M Rudas; A Rottenfusser; M Knauer; H Eiter; F Fitzal; K Dieckmann; R M Mader; M Gnant; C C Zielinski; G G Steger; M Preusser; R Bartsch
Journal:  Br J Cancer       Date:  2012-01-10       Impact factor: 7.640

8.  Integration of Breast Cancer Secretomes with Clinical Data Elucidates Potential Serum Markers for Disease Detection, Diagnosis, and Prognosis.

Authors:  Yvonne S Ziegler; James J Moresco; John R Yates; Ann M Nardulli
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

9.  Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer.

Authors:  Rachna Malani; Martin Fleisher; Priya Kumthekar; Jeffrey Raizer; Elena Pentsova; Xuling Lin; Antonio Omuro; Morris D Groves; Nancy U Lin; Michelle Melisko; Andrew B Lassman; Suriya Jeyapalan; Andrew Seidman; Anna Skakodub; Adrienne Boire; Lisa M DeAngelis; Marc Rosenblum
Journal:  J Neurooncol       Date:  2020-06-06       Impact factor: 4.130

10.  Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study.

Authors:  Allison M Martin; Daniel N Cagney; Paul J Catalano; Laura E Warren; Jennifer R Bellon; Rinaa S Punglia; Elizabeth B Claus; Eudocia Q Lee; Patrick Y Wen; Daphne A Haas-Kogan; Brian M Alexander; Nancy U Lin; Ayal A Aizer
Journal:  JAMA Oncol       Date:  2017-08-01       Impact factor: 31.777

View more
  1 in total

Review 1.  Immune Checkpoint Inhibitors in Cancer Therapy.

Authors:  Yavar Shiravand; Faezeh Khodadadi; Seyyed Mohammad Amin Kashani; Seyed Reza Hosseini-Fard; Shadi Hosseini; Habib Sadeghirad; Rahul Ladwa; Ken O'Byrne; Arutha Kulasinghe
Journal:  Curr Oncol       Date:  2022-04-24       Impact factor: 3.109

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.